Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
12 hedge funds and large institutions have $995K invested in Evoke Pharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 7 closing their positions.
22.35% more ownership
Funds ownership: 3.05% → 25.4% (+22%)
25% less funds holding
Funds holding: 16 → 12 (-4)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
40% less capital invested
Capital invested by funds: $1.67M → $995K (-$673K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Corsair Capital Management
New York
|
+$61.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.02K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$100 |
| 4 |
Citigroup
New York
|
+$21 |
| 5 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$366K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$26.3K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.3K |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.64K |
EVOK Hedge Fund Activity: Q3 2024 in Review
12 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2024, worth a combined $995K — down 40% from $1.67M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EVOK and 3 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Corsair Capital Management, opening a new position worth an estimated $61.5K. The largest seller was Altium Capital Management, exiting entirely with an estimated $366K sold.
- 12 institutional investors held Evoke Pharma (EVOK) as of Q3 2024, down from 16 in Q2 2024.
- Funds reported $995K of Evoke Pharma stock for Q3 2024, down 40% quarter-over-quarter.
- 3 funds opened new Evoke Pharma positions in Q3 2024 and 7 closed out, a net change of -4 holders.
- The largest Evoke Pharma buyer in Q3 2024 was Corsair Capital Management, an estimated $61.5K added.
- The largest Evoke Pharma seller in Q3 2024 was Altium Capital Management, an estimated $366K sold.
Based on aggregated 13F filings for Q3 2024.